Related references
Note: Only part of the references are listed.The Influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Silodosin in Healthy Chinese Volunteers
Zining Wang et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain
Torill Fladvad et al.
PHARMACOGENETICS AND GENOMICS (2013)
Morphine metabolism, transport and brain disposition
Simona De Gregori et al.
METABOLIC BRAIN DISEASE (2012)
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer
Ken-ichi Fujita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Pharmacogenetics in medico-legal context
A. Sajantila et al.
FORENSIC SCIENCE INTERNATIONAL (2010)
Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites
Andrea S. Blevins-Primeau et al.
CANCER RESEARCH (2009)
Meta-analysis of the relevance of the OPRM1 118A > G genetic variant for pain treatment
Carmen Walter et al.
PAIN (2009)
A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia
Alex T. Sia et al.
ANESTHESIOLOGY (2008)
Preoperative psychologic and demographic predictors of pain perception and tramadol consumption using intravenous patient-controlled analgesia
Germano De Cosmo et al.
CLINICAL JOURNAL OF PAIN (2008)
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief
D. Campa et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes
Vincent C. Peterkin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain:: OPRM1 and COMT gene
Cielito C. Reyes-Gibby et al.
PAIN (2007)
The μ-opioid receptor gene polymorphism 118A > G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carries
Bruno G. Oertel et al.
PHARMACOGENETICS AND GENOMICS (2006)
Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty
W. -Y. Chou et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2006)
Relevance of frequent μ-opioid receptor polymorphisms for opioid activity in healthy volunteers
J. Lötsch et al.
PHARMACOGENOMICS JOURNAL (2006)
The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease
P Klepstad et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2004)
A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain
J Riley et al.
PALLIATIVE MEDICINE (2004)
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene
DL Kroetz et al.
PHARMACOGENETICS (2003)
Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy
T Hirota et al.
DRUG METABOLISM AND DISPOSITION (2003)
Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance
CR Bhasker et al.
PHARMACOGENETICS (2000)
Share Paper
